Full-Time
Confirmed live in the last 24 hours
Develops genomic tests for cancer diagnosis
$140k - $175kAnnually
Senior
San Bruno, CA, USA
The company will consider candidates from the West Coast.
You match the following Veracyte's candidate preferences
Employers are more likely to interview you if you match these preferences:
Veracyte develops and sells advanced genomic tests for the early detection and diagnosis of various cancers. Their tests analyze genetic information from non-invasive samples like nasal swabs or tissue biopsies, providing insights into the presence and progression of cancer. This allows healthcare providers, such as hospitals and clinics, to make informed treatment decisions tailored to individual patients. Veracyte stands out from competitors by focusing on non-invasive testing methods and continuously investing in research to expand their product offerings. Their goal is to improve cancer diagnosis accuracy, leading to better patient outcomes and more efficient healthcare resource use.
Company Size
501-1,000
Company Stage
IPO
Total Funding
$69.4M
Headquarters
San Francisco, California
Founded
2008
Help us improve and share your feedback! Did you find this helpful?
Performance Bonus
Stock Options
Remote Work Options
HighTower Advisors LLC makes new investment in Veracyte, Inc. (NASDAQ:VCYT).
That's why Veracyte is testing their Decipher Prostate Genomic Classifier, an AI-based transcriptome genetic test that was developed using primarily White American males, on Black African American males to see if it offers clinicians an improvement over clinical factors alone in guiding prostate cancer treatment decisions.
SOUTH SAN FRANCISCO, Calif. - Veracyte, Inc. (NASDAQ:VCYT), a global cancer diagnostics company, announced today the addition of Brent Shafer and Tom Miller, Ph.D., to its board of directors, effective immediately.
SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced the appointment of Brent Shafer and Tom Miller, Ph.D., to its board of directors, effective immediately.
Looking ahead, Veracyte plans to launch an MRD assay in 2026 and is working on policy updates with commercial payers for LCD products.